Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics | RCV002473033 | SCV000614962 | uncertain significance | not provided | 2021-08-05 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002527519 | SCV003267666 | likely benign | Spastic paraplegia | 2024-01-04 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002525073 | SCV003726994 | uncertain significance | Inborn genetic diseases | 2022-08-30 | criteria provided, single submitter | clinical testing | The c.5583G>C (p.W1861C) alteration is located in exon 10 (coding exon 9) of the SACS gene. This alteration results from a G to C substitution at nucleotide position 5583, causing the tryptophan (W) at amino acid position 1861 to be replaced by a cysteine (C). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001276941 | SCV001463607 | uncertain significance | Charlevoix-Saguenay spastic ataxia | 2020-09-16 | no assertion criteria provided | clinical testing |